In a latest report issued by The New York Times and Forbes the federal agency FDA is accused of not assessing the post marketing surveillance study effectively and that the statement that the rate of bleeding events linked to are no higher than those associated with Warfarin is flawed and needs to be re-evaluated and reconsidered. Pradaxa is a blood thinning and anticoagulant drug widely used across the United States to treat occurrence of thrombosis and embolus in the blood that are some of the main reasons of heart attack. However in the light of that drug was under the scrutiny of FDA and other federal agencies.

Previous ArticleFDA Expands Use Of Xarelto To Treat, Reduce Recurrence Of Blood Clots Next ArticleTekturna May Be Harmful In Type 2 Diabetics With Heart, Kidney Problems
Verdicts and Settlements
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers